{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:24:07Z","timestamp":1759742647188,"version":"3.37.3"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III","award":["PI16\/00837-PI16\/00678"],"award-info":[{"award-number":["PI16\/00837-PI16\/00678"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Previously selected lamivudine resistance-associated mutations (RAMs) may remain archived within the proviral HIV-DNA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the ability of proviral DNA genotyping to detect lamivudine RAMs in HIV-1 virologically suppressed participants; the correlation between Sanger and next generation sequencing (NGS); and predictive factors for detection of lamivudine RAMs in proviral DNA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cross-sectional study of participants on stable antiretroviral therapy and suppressed for \u22651\u2009year. Analysis of proviral DNA was performed by Sanger sequencing in whole blood and by NGS in PBMCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We analysed samples from 102 subjects (52 with and 50 without lamivudine RAMs in historical plasma RNA-genotypes). Among participants with previous lamivudine resistance, Sanger sequencing detected RAMs in 26.9%. Detection rates significantly increased using NGS: 47.9%, 64.6%, 75% and 87.5% with the 20%, 10%, 5% and 1% thresholds, respectively. As for participants without historical lamivudine resistance, Sanger detected the RAMs in 1\/49 (2%), and NGS (5% threshold) in 8\/45 (17.8%). Multivariate models fitted to the whole population revealed that having a history of lamivudine resistance was a risk factor for detection of lamivudine RAMs by NGS. Among participants with historical lamivudine resistance, multivariate analysis showed that a longer time since HIV diagnosis was associated with persistence of archived mutations by NGS at thresholds of &amp;gt;10% [OR 1.10 (95% CI: 1.00\u20131.24)] and &amp;gt;5% [OR 1.16 (95% CI: 1.02\u20131.32)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Proviral DNA Sanger sequencing does not detect the majority of historical lamivudine RAMs. NGS increases the sensitivity of detection at lower thresholds, although the relevance of these minority populations with lamivudine RAMs needs further evaluation.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkab323","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T20:05:53Z","timestamp":1629230753000},"page":"3263-3271","source":"Crossref","is-referenced-by-count":7,"title":["Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3446-0545","authenticated-orcid":false,"given":"Rocio","family":"Montejano","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz\u2014IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Dominguez-Dominguez","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"de Miguel","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz\u2014IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rial-Crestelo","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Esteban-Cantos","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz\u2014IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Aranguren-Rivas","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Garc\u00eda-\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Alejos","sequence":"additional","affiliation":[{"name":"Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otilia","family":"Bisbal","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Santacreu-Guerrero","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asunci\u00f3n","family":"Hernando","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bermejo-Plaza","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julen","family":"Cadi\u00f1anos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz\u2014IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Mayoral","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario La Paz\u2014IdiPAZ, Paseo de la Castellana 261 28046, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Miguel","family":"Castro","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario La Paz\u2014IdiPAZ, Paseo de la Castellana 261 28046, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Moreno","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario La Paz\u2014IdiPAZ, Paseo de la Castellana 261 28046, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz","family":"Martin-Carbonero","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario La Paz\u2014IdiPAZ, Paseo de la Castellana 261 28046, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Rod\u00e9s","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz\u2014IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-4736","authenticated-orcid":false,"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rubio","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department, Hospital Universitario 12 de Octubre\u2014Imas12, Av. de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-9450","authenticated-orcid":false,"given":"Jos\u00e9 Ram\u00f3n","family":"Arribas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz\u2014IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"2021111722575512600_dkab323-B1"},{"year":"2020","key":"2021111722575512600_dkab323-B2"},{"key":"2021111722575512600_dkab323-B3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"2021111722575512600_dkab323-B4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/QAI.0000000000002595","article-title":"Switching to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide in adults with HIV and M184V\/I mutation","volume":"86","author":"Perez-Valero","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021111722575512600_dkab323-B5","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021111722575512600_dkab323-B6","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/JCM.37.7.2291-2296.1999","article-title":"Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase","volume":"37","author":"Schuurman","year":"1999","journal-title":"J Clin Microbiol"},{"key":"2021111722575512600_dkab323-B7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.antiviral.2009.09.015","article-title":"Clinical management of HIV-1 resistance","volume":"85","author":"Paredes","year":"2010","journal-title":"Antiviral Res"},{"key":"2021111722575512600_dkab323-B8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.virusres.2016.10.019","article-title":"Deep sequencing for HIV-1 clinical management","volume":"239","author":"Casadell\u00e0","year":"2017","journal-title":"Virus Res"},{"key":"2021111722575512600_dkab323-B9","first-page":"2249","article-title":"Differential detection of M184V\/I between plasma historical HIV genotypes and HIV proviral DNA from PBMCs","volume":"75","author":"Margot","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021111722575512600_dkab323-B10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jviromet.2017.10.016","article-title":"Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy","volume":"251","author":"Allavena","year":"2018","journal-title":"J Virol Methods"},{"key":"2021111722575512600_dkab323-B11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jac\/dkx366","article-title":"No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir","volume":"73","author":"Perrier","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021111722575512600_dkab323-B12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/bioinformatics\/btr026","article-title":"Quality control and preprocessing of metagenomic datasets","volume":"27","author":"Schmieder","year":"2011","journal-title":"Bioinformatics"},{"key":"2021111722575512600_dkab323-B13","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/bioinformatics\/btr507","article-title":"FLASH: fast length adjustment of short reads to improve genome assemblies","volume":"27","author":"Magoc","year":"2011","journal-title":"Bioinformatics"},{"key":"2021111722575512600_dkab323-B14","doi-asserted-by":"crossref","first-page":"W271","DOI":"10.1093\/nar\/gky349","article-title":"geno2pheno[ngs-freq]: a genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data","volume":"46","author":"D\u00f6ring","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2021111722575512600_dkab323-B15","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkaa479","article-title":"Long- term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: week 96 results of ART-PRO pilot study","volume":"76","author":"Rial-Crestelo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2021111722575512600_dkab323-B16","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/jac\/dkx232","article-title":"RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients","volume":"72","author":"Alidjinou","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021111722575512600_dkab323-B17","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1093\/jac\/dky315","article-title":"Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia","volume":"73","author":"Rodriguez","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021111722575512600_dkab323-B18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/jac\/dkab002","article-title":"Deep sequencing analysis of M184V\/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial)","volume":"76","author":"Delaugerre","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2021111722575512600_dkab323-B19","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021111722575512600_dkab323-B20","doi-asserted-by":"crossref","first-page":"104207","DOI":"10.1016\/j.jcv.2019.104207","article-title":"Routine drug resistance testing in HIV-1 proviral DNA, using an automated next-generation sequencing assay","volume":"121","author":"Alidjinou","year":"2019","journal-title":"J Clin Virol"},{"key":"2021111722575512600_dkab323-B21","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3018(18)30177-2","article-title":"Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study","volume":"5","author":"Inzaule","year":"2018","journal-title":"Lancet HIV"},{"key":"2021111722575512600_dkab323-B22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/apc.2019.0198","article-title":"Virological outcome after choice of antiretroviral regimen guided by proviral HIV-1 DNA genotyping in a real-life cohort of HIV-infected patients","volume":"34","author":"Meybeck","year":"2020","journal-title":"AIDS Patient Care STDS"},{"key":"2021111722575512600_dkab323-B23","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021111722575512600_dkab323-B24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1128\/JCM.00030-16","article-title":"Deep sequencing of HIV-1 RNA and DNA in newly diagnosed patients with baseline drug resistance showed no indications for hidden resistance and is biased by strong interference of hypermutation","volume":"54","author":"Dauwe","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2021111722575512600_dkab323-B25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"2021111722575512600_dkab323-B26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkq544","article-title":"Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia","volume":"66","author":"Wirden","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2021111722575512600_dkab323-B27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2012.01002.x","article-title":"Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication","volume":"13","author":"Delaugerre","year":"2012","journal-title":"HIV Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/12\/3263\/41136338\/dkab323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/12\/3263\/41136338\/dkab323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T19:07:17Z","timestamp":1725649637000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/12\/3263\/6359551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,8,30]]},"published-print":{"date-parts":[[2021,11,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab323","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,8,30]]}}}